Childhood pneumonia remains a leading cause of morbidity and mortality worldwide despite advances in prevention and care. Modern management emphasizes rapid clinical assessment, evidence-based antibiotic selection, targeted use of diagnostics, supportive care, and systems-level antimicrobial stewardship. For most non-severe community-acquired cases, oral amoxicillin remains the recommended first-line agent; hospitalization and parenteral therapy are reserved for severe disease or complications. Recent WHO guidance (2024) and specialist society reviews reinforce simplified classification, outpatient management when safe, and shorter antibiotic courses for well children while stressing careful follow-up. Advances in point-of-care diagnostics (rapid antigen assays, multiplex PCR, and biomarker-guided approaches such as procalcitonin) increasingly assist in distinguishing bacterial from viral causes and allow more precise antibiotic use. Adjunctive therapies (e.g., corticosteroids) show promise in selected severe cases but have mixed evidence and require cautious patient selection. Crucially, pediatric antimicrobial stewardship programs (ASPs), integrated with local protocols and diagnostic algorithms, reduce unnecessary antibiotic exposure, resistance selection, and adverse events. This article reviews contemporary guideline recommendations, diagnostic innovations, stewardship strategies, and evidence around adjunctive treatments; it also proposes a pragmatic research design to evaluate a bundled intervention (diagnostics + stewardship + guideline-based prescribing) in a mixed-resource pediatric population.

Childhood pneumonia, amoxicillin, antimicrobial stewardship, diagnostics, procalcitonin, community-acquired pneumonia, corticosteroids, clinical guidelines, outpatient management, point-of-care testing.

World Health Organization. Guideline on management of pneumonia and diarrhoea in children up to 10 years of age. WHO; 2024.

World Health Organization. Pneumonia fact sheet. WHO; 2022.

Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011.

Sauteur PMM, et al. Childhood community-acquired pneumonia. Lancet Respir Med. 2023.

Kok HC, et al. Antibiotics for Paediatric Community-Acquired Pneumonia — review. [PMC] 2025.

Girotto JE, et al. Pediatric Antibiotic Stewardship Programs: The Path Forward. Clin Infect Dis / PMC. 2025.

Van de Maat JS, et al. Diagnostic testing and antibiotic stewardship for pneumonia. Curr Opin Pediatr. 2025.

Daley MF, et al. Improving Antibiotic Prescribing for Children with Community-Acquired Pneumonia: Implementation interventions. J Pediatr. 2024.

Wu JY, et al. Efficacy and safety of corticosteroids for the treatment of community-acquired pneumonia: systematic review/meta-analysis. Crit Care. 2023.

Dequin PF, et al. Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023.

British Thoracic Society. Paediatric Community Acquired Pneumonia resources and QI tools. BTS; 2024.

Texas Children’s Hospital. Community-Acquired Pneumonia Guideline (institutional standard). 2024.